EAM
During the course of the past 40 years, we have launched and developed five highly-respected journals, which largely fund our charitable activities. This includes our grants programme, biennial congress, and the European Academy of Microbiology (EAM).
The EAM is a leadership group of around 150 eminent microbiology experts who came together in 2009 to amplify the impact of microbiology and microbiologists in Europe.
Past activities
| Year | EAM’s Key initiatives |
| 2011 | Article – the enemy within us: lessons from the 2011 European Escherichia coli O104:H4 outbreak |
| 2011 | Workshop – participation at the FEMS Congress 2011 included a 2 hour EAM/EMF-led Keynote Lecture and Roundtable Discussion on “Emerging Diseases — Pandemics, Drug Resistance and Vaccines” |
| 2012 | Seminar – a seminar addressing Coinfections was hosted by the European Academy of Microbiology (EAM) and the German National Academy of Sciences in Leopoldina. Ten speakers presented. A Special Edition ‘Co-infections’ was produced by the EAM and EMF in FEMS Journal Pathogens and Disease. It included a total of 10 x mini reviews / research articles. |
| 2013 | Workshop – Infection Diagnostics and Infection Biology |
| 2014 | Workshop – a retreat workshop with a number of presentations |
| 2015 | Special event – at FEMS 2015, EAM chaired the special event ‘Microbiome and human health’ |
| 2016 | Workshop – a retreat workshop with a number of presentations |
| 2017 | Workshop – at FEMS2017, EAM chaired a workshop ‘Bacterial Survival Strategies’ |
| 2018 | Workshop – a retreat workshop with a number of presentations |
Induced erythromycin resistance promotes solithromycin resistance in S. aureus
The aim of this study was to determine whether in vitro induced erythromycin resistance facilitates the cross-resistance to the novel fluoroketolide, solithromycin, in Staphylococcus aureus. Long-term exposure of erythromycin results in resistance to ketolides in S. aureus through drug binding site mutations. These results demonstrate that since erythromycin has been used clinically for a long time, it is necessary to carefully evaluate the rewards and risks when prescribing solithromycin for the treatment of infectious diseases.
